Who will get a third Covid vaccine in UK? People eligible for jab, and how they differ from ‘booster’ shots

Watch more of our videos on Shots! 
and live on Freeview channel 276
Visit Shots! now

This article contains affiliate links. We may earn a small commission on items purchased through this article, but that does not affect our editorial judgement.

The third jabs will not form part of the mass Covid-19 booster programme, with a separate announcement expected from the government on this soon

Millions of people with severely weakened immune systems will be offered a third dose of a Covid-19 vaccine, but the mass rollout is still on hold.

Ministers have put the mass booster programme on hold to prioritise those with serious illnesses, although a separate announcement on this is expected soon.

Hide Ad
Hide Ad

We want to hear from you: let us know what you think about this story and be part of the debate in our comments section below

People with conditions including leukaemia, advanced HIV, severe autoimmune diseases and recent organ transplants who are over the age of 12 are among those who will be given a third vaccine dose, following recommendation from the Joint Committee on Vaccination and Immunisation (JCVI).

Health officials said the third jabs are not boosters, which are intended to prolong people’s immunity, but instead form part of the primary vaccination schedule for up to 500,000 vulnerable UK patients.

Who is eligible for a third jab?

People considered to have had severe immunosuppression at the time of vaccination will be offered a third dose.

This includes the following groups:

Hide Ad
Hide Ad
  • People with primary or acquired immunodeficiency states at the time of vaccination due to condition. This includes:

    • acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) who were under treatment or within 12 months of achieving cure
    • people under follow up for a chronic lymphoproliferative disorders, including haematological malignancies 
    • immunosuppression due to HIV/AIDS with a current CD4 count of <200 cells/µl for adults Primary or acquired cellular and combined immune deficiencies – those with lymphopenia (<1,000 lymphocytes/ul) or with a functional lymphocyte disorder
    • people who have received an allogeneic or an autologous stem cell transplant in the previous 24 months
    • people who received a stem cell transplant more than 24 months ago but have ongoing immunosuppression or graft versus host disease (GVHD)
    • persistent agammaglobulinemia (IgG < 3g/L) due to primary immunodeficiency or secondary to disease / therapy
  • People on immunosuppressive or immunomodulatory therapy at the time of vaccination. This includes:
    • people who were receiving or had received immunosuppressive therapy for a solid organ transplant in the previous six months
    • people who were receiving or have received in the previous three months targeted therapy for autoimmune disease
    • people who were receiving or have received in the previous six months immunosuppressive chemotherapy or radiotherapy for any indication
  • People with chronic immune-mediated inflammatory disease who were receiving or have received immunosuppressive therapy before vaccination. This includes:
    • high dose corticosteroids (equivalent ≥ 20mg prednisolone per day) for more than 10 days in the previous month
    • long term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the previous three months
    • non-biological oral immune modulating drugs, such as methotrexate >20mg per week (oral and subcutaneous), azathioprine >3.0mg/kg/day; 6-mercaptopurine >1.5mg/kg/day, mycophenolate >1g/day) in the previous three months
    • certain combination therapies at individual doses lower than above, including those on ≥5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the previous three months
  • Individuals who have received high dose steroids (equivalent to >40mg prednisolone per day for more than a week) for any reason in the month before vaccination. Those who received brief immunosuppression (≤40mg prednisolone per day) for an acute episode, and individuals on replacement corticosteroids for adrenal insufficiency, are not considered severely immunosuppressed sufficient to have prevented response to the primary vaccination.

    When will the mass booster programme start?

    Health Secretary Sajid Javid said the government is continuing to plan for a mass booster programme, expected to begin this month, and said people most at-risk from Covid-19 will be prioritised.

    However, the JCVI is still deliberating on the potential benefits of booster vaccines for the wider population and is awaiting further evidence to inform its decision.

    It is also yet to decide on any extension of the vaccine programme to include all healthy 12 to 15-year-olds.

    Giving its recommendation on Wednesday (1 September), the JCVI said people who were severely immunosuppressed at the time of their first or second dose of a coronavirus vaccine may not have been able to mount a full response to vaccination, meaning they could be less protected than the wider population.

    Hide Ad
    Hide Ad

    The committee said studies are ongoing to see how effective a third dose is for this group of people, and as it is considered unlikely to cause any harm, the JCVI has decided that a third jab can be safely offered and might boost protection.

    The preference for children in this category who are aged between 12 and 17 is the Pfizer vaccine, while those aged 18 and over will be given either Pfizer or Moderna.

    Both of these jabs are mRNA vaccines and almost all of the data so far on third doses is based on this kind of vaccine.

    The timing of a third dose will be made by a patient’s specialist doctor, but the jab will usually be given at least eight weeks after the second dose, with some flexibility on that.

    Hide Ad
    Hide Ad

    The recommendation does not apply to all those considered clinically extremely vulnerable, but is estimated to include between 400,000 and 500,000 people, or less than one per cent of the population.

    Mr Javid said he has accepted the JCVI’s recommendation, stating: “We know people with specific conditions that make them particularly vulnerable to Covid-19 may have received less protection against the virus from two vaccine doses.

    “I am determined to ensure we are doing all we can to protect people in this group and a third dose will help deliver that.

    “The NHS will contact people as soon as possible to discuss their needs and arrange an appointment for a third dose where clinically appropriate.

    Hide Ad
    Hide Ad

    “This is not the start of the booster programme – we are continuing to plan for this to begin in September to ensure the protection people have built from vaccines is maintained over time and ahead of the winter.

    “We will prioritise those most at risk to Covid-19, including those who are eligible for a third primary vaccine, for boosters based on the final advice of the JCVI.”

    GPs and consultants will be involved in identifying eligible patients and delivering jabs, with more details to be set out.

    A message from the editor:

    Thank you for reading. NationalWorld is a new national news brand, produced by a team of journalists, editors, video producers and designers who live and work across the UK. Find out more about who’s who in the team, and our editorial values. We want to start a community among our readers, so please follow us on Facebook, Twitter and Instagram, and keep the conversation going. You can also sign up to our newsletters and get a curated selection of our best reads to your inbox every day.

    Comment Guidelines

    National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.